A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This trial is comprised of a 4-week randomized, double-blind, placebo-controlled treatment
period followed by an optional 8-week open-label extension (OLE) period.
This trial will evaluate the efficacy and safety of oral PRAX-114 flexibly dosed at 40 to 60
mg for 4 weeks compared to placebo in adults with PTSD. The OLE period consisting of
treatment with 40 mg PRAX-114 for 8 weeks will provide additional efficacy and safety data.